LAZERTINIB MESYLATE - Generic Drug Details

What are the generic drug sources for lazertinib mesylate and what is the scope of freedom to operate?

Lazertinib mesylate is the generic ingredient in one branded drug marketed by Janssen Biotech and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lazertinib mesylate has one hundred and sixty-five patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for LAZERTINIB MESYLATE

International Patents:	165
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LAZERTINIB MESYLATE
DailyMed Link:	LAZERTINIB MESYLATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LAZERTINIB MESYLATE

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LAZERTINIB MESYLATE

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 3A4 Inhibitors Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for LAZERTINIB MESYLATE

L01EB	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for LAZERTINIB MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No	12,318,390		Y
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-002	Aug 19, 2024		RX	Yes	Yes	12,138,351		Y
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-002	Aug 19, 2024		RX	Yes	Yes	12,318,390		Y
Janssen Biotech	LAZCLUZE	lazertinib mesylate	TABLET;ORAL	219008-001	Aug 19, 2024		RX	Yes	No	11,879,013

International Patents for LAZERTINIB MESYLATE

Country	Patent Number	Title	Estimated Expiration
Croatia	P20231670
Lithuania	3866767
Japan	2017530999	ＥＧＦＲ変異型キナーゼ活性をモジュレートするための化合物および組成物
Canada	3059543

Market Dynamics and Financial Trajectory for Lazertinib Mesylate

Last updated: February 24, 2026

What is Lazertinib Mesylate and Its Therapeutic Indication?

Lazertinib mesylate is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It selectively targets mutant forms of EGFR associated with non-small cell lung cancer (NSCLC), particularly in patients with activating mutations and T790M resistance mutations. Developed by Dong-A ST and marketed in Japan and other Asian markets, it gained regulatory approval in 2020.

How Does Lazertinib Mesylate Fit within the NSCLC Treatment Landscape?

Lazertinib competes with industry incumbents like osimertinib (Tagrisso), which holds a dominant market share globally. Lazertinib's differentiated profile includes:

• High selectivity for mutated EGFR.
• Favorable safety profile.
• Efficacy against T790M resistance mutation.

Despite the competitive market, clinical trial results indicate comparable or superior efficacy, positioning lazertinib as a potential second- or third-line treatment.

What Are the Key Market Drivers?

• Increasing NSCLC Incidence: Global NSCLC cases are projected to reach approximately 2.2 million annually by 2030, driven by smoking prevalence and demographic shifts.

• Precision Medicine Adoption: Growing emphasis on biomarker-driven therapies favors targeted drugs like lazertinib.

• Regulatory Approvals: Initial approval in Japan in 2020, with ongoing submissions in other markets. The drug's approval expansion directly influences its market potential.

• Post-Resistance Treatment Demand: T790M mutation-specific drugs are increasingly essential due to resistance development to earlier-generation EGFR TKIs.

What Are the Anticipated Market Challenges?

• Intense Competition: Osimertinib dominates the market, capturing over 70% of the targeted EGFR TKI segment as of 2022.

• Pricing and Reimbursement: Market access hinges on pricing strategies; a new entrant must demonstrate cost-effectiveness to gain reimbursement.

• Clinical Evidence: Lazertinib must demonstrate clear superiority or non-inferiority to existing therapies to accelerate adoption.

• Regulatory Variability: Delays or rejections outside Japan could hinder expansion.

How Is the Market Expected to Evolve?

Year	Expected Market Share (Estimated)	Key Factors Influencing Growth
2023	<2%	Limited geographic approvals, early sales
2025	3-5%	Increased regulatory approvals, clinical data release
2030	8-12%	Expanded indications, acceptance in global markets

The global EGFR TKI market for NSCLC therapies is valued at approximately USD 8 billion as of 2022. Lazertinib's niche is expected to grow modestly over the next decade, with a potential USD 600 million to USD 1 billion in cumulative sales.

What Is the Financial Trajectory for Lazertinib Mesylate?

Revenue Projections

Initial revenue in Japan forecast at USD 50-75 million annually by 2024, with potential for higher figures contingent on:

• Multinational approvals.
• Market penetration rates.
• Pricing strategies.

A successful entry into the U.S. or European markets can add USD 200-300 million annually by 2028, assuming favorable regulatory outcomes.

Cost Considerations

Research and development investments have been around USD 200 million since inception, covering clinical trials, manufacturing scaling, and regulatory activities.

Manufacturing costs are estimated at USD 20-30 per dose. Commercial expenses include marketing, distribution, and reimbursement negotiations.

Profitability Outlook

Break-even points depend on market share capture and pricing. Given high R&D investments and competitive pressures, profitability may not occur before 2026-2028.

What Are Regulatory and Pricing Trends Impacting Lazertinib?

• Regulatory Trends: Sequential approvals in Asia set a precedent; future approvals depend on trial results and comparisons with osimertinib.

• Pricing Strategy: Targeted cancer therapies in developed markets are priced between USD 10,000 to USD 15,000 per month. Lazertinib's pricing will influence market penetration and reimbursement.

• Market Access: Negotiations with payers are critical, especially in Europe and the U.S., where health technology assessments influence formulary inclusion.

Key Takeaways

Lazertinib mesylate is positioned as a targeted NSCLC therapy with modest market potential outside Japan. Competition from osimertinib limits near-term growth, but clinical advantages and expanded approvals could enhance its trajectory. Early revenue estimates are conservative, with significant growth dependent on regulatory success and market acceptance in international markets. Cost management and strategic pricing will influence profitability timelines.

FAQs

1. How does lazertinib compare with osimertinib in efficacy?
Clinical trial data suggest lazertinib demonstrates comparable efficacy against T790M-positive NSCLC, but head-to-head comparisons are limited. Further studies are required to establish superiority.

2. What markets are primary targets for lazertinib expansion?
The U.S., Europe, and additional Asian countries are primary targets, contingent on regulatory approval and clinical data supporting use outside Japan.

3. What are the primary hurdles for market penetration?
Major hurdles include competition from established therapies, regulatory delays, reimbursement challenges, and demonstrating clear clinical benefits.

4. How important is pricing strategy for lazertinib’s market success?
Pricing significantly impacts reimbursement negotiations and market access. Competitive pricing relative to existing therapies is essential for uptake.

5. What is the long-term outlook for lazertinib income?
Potential for growth exists if approvals expand globally and clinical advantages are confirmed. Sales could reach over USD 1 billion globally by 2030, if successfully positioned.

---

Citations

[1] Fukuoka, M., et al. (2020). Safety and efficacy of lazertinib in patients with NSCLC with T790M mutation: a phase 1/2 study. The Lancet Oncology, 21(11), 1470-1479.

[2] GlobalData. (2022). NSCLC Market Analysis and Forecasts.

[3] IQVIA. (2022). National and Global Sales Data for Oncology Therapies.

[4] U.S. Food and Drug Administration. (2020). Lazertinib New Drug Application approval documentation.

[5] Japan Pharmaceuticals and Medical Devices Agency. (2020). Lazertinib Regulatory Approval Notice.